About Fruzaqla ®▼ (fruquintinib)
Indication
Fruzaqla is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine-tipiracil or regorafenib.1
Mode of Action
Fruzaqla is a non-chemotherapy that limits, because of its selectivity, off target kinase activity, allowing for drug exposure achieving sustained target inhibition.2,4
.Preclinical activity does not necessarily correlate with clinical outcomes.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
References:
1. Fruzaqla EU Summary of product characteristics - latest approved version
2. Sun Q, et al. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-1645.
3. Zhang Y. et al. Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer. Cancer Manag Res. 2019;11:7787-7803.
4. Qin S. et al. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J Hematol Oncol. 2019 Mar 12;12(1):27.
Abbreviations:
VEGF: Vascular Endothelial Growth Factor
EGFR: Epidermal Growth Factor Receptor
mCRC: metastatic Colorectal Cancer
VEGFR: Vascular Endothelial Growth Factor Receptor
smpc
price
